Berkery Noyes said Accolade would likely command an attractive multiple in a sale process, anywhere from 3x to 5x revenue or 8x to 15x EBITDA. “There are very few players with the same scale and growth trajectory that are serving self-insured employers and payors,” Berkery noted.